Bimekizumab efficacy and safety in Chinese patients with psoriasis in the <scp>BE SHINING</scp> Phase 3 study
Bimekizumab treatment was well tolerated and led to significantly higher clinical response rates versus placebo, including complete skin clearance, in Chinese patients with moderate to severe psoriasis. Findings were consistent with global studies.
Authors
- Bengt Hoepken (ORCID: https://orcid.org/0000-0002-7487-8559)
- X. Man
- Delphine Deherder (ORCID: https://orcid.org/0000-0002-7336-1988)
- Jinyan Wang (ORCID: https://orcid.org/0000-0001-7440-4073)
- Lin Cai (ORCID: https://orcid.org/0000-0002-7045-3625)
- Aihua Wei
- Ying Chen
- Jun Gao
- Tingting Lei
- Weiwei Sun
- the BE SHINING Study Group
- Jianzhong Zhang
Institutions
- Beijing Tongren Hospital (CN)
- Peking University (CN)
- Urban College of Boston (US)
- Ningbo No. 2 Hospital (CN)
- Peking University People's Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- UCB Pharma (Germany) (DE)
- UCB Pharma (Belgium) (BE)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1111/jdv.70350
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00